Evolus Achieves Q4 2025 Profitability, Projects Sustainable Annual Profitability in 2026, and Raises Long-Term Outlook
EOLS is trading near its 52-week low of $5.61 (0.4% below the low).
Summary
Evolus announced preliminary Q4 and full-year 2025 net revenues, reaffirming positive non-GAAP operating income for Q4 2025 and projecting sustainable annual profitability starting in 2026, alongside strong 2026 guidance and an updated long-term financial outlook.
Key Events · Earnings and Guidance · EOLS
-
Achieved Q4 2025 Profitability
The company reaffirmed positive non-GAAP operating income of $5 million to $7 million for the fourth quarter of 2025.
-
Strong 2025 Revenue Growth
Preliminary unaudited net revenue for full-year 2025 is expected to be between $295.5 million and $297.5 million, representing 11% to 12% growth over the prior year.
-
Positive 2026 Guidance
Total net revenues for 2026 are projected to be between $327 million and $337 million, an 11% to 13% increase, with sustainable annual profitability expected to begin in 2026.
-
Updated Long-Term Outlook
The 2028 long-term financial outlook was updated to reflect total net revenue of $450 million to $500 million and non-GAAP operating income margins of 13% to 15%.
Analysis · EOLS · Life Sciences
Evolus's preliminary financial results indicate a significant milestone with the achievement of positive non-GAAP operating income in Q4 2025, a key indicator of operational efficiency and financial health. The projection of sustainable annual profitability beginning in 2026, coupled with double-digit revenue growth guidance for 2026 and an increased long-term revenue outlook for 2028, suggests a strong growth trajectory and improved financial discipline. This news, especially while the stock is trading near its 52-week low, could signal a potential turning point for investor sentiment, highlighting the company's ability to gain market share and diversify its product portfolio.
How filings like this one have moved
In the 30 days to Sep 18, 2026, 35.6% of the 1155 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.41%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, EOLS was trading at $5.59 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $372.1M. The 52-week trading range was $5.61 to $17.12. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.